Scientific basis for contact lens accessory downclassification questioned by ex-FDAer Charles Kyper.
This article was originally published in The Gray Sheet
Executive Summary
CONTACT LENS ACCESSORIES DOWNCLASSIFICATION PROPOSAL: SCIENTIFIC BASIS QUESTIONED by Charles Kyper, former director of reclassification and compliance in the Office of Device Evaluation, Center for Devices and Radiological Health, in April 20 comments to FDA. The agency's proposed rule to reclassify contact lens accessories, published in the April 1 Federal Register ("The Gray Sheet" April 8, In Brief), "neither summarizes, nor provides a bibliography of, the supporting safety and effectiveness information thereby not providing an opportunity for interested persons to support, or challenge, the proposed reclassification on the sufficiency of this supporting information," Kyper says. Kyper became a consultant at C.L. McIntosh when he left FDA in August 1994, and now heads up the consulting firm Kyper & Associates.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.